Silexion Therapeutics Corp. has received a notice from the Nasdaq Stock Market LLC regarding a regulatory issue related to its stock listing. The Listing Qualifications Department informed Silexion that the closing bid price of its ordinary shares has been below the minimum $1.00 per share requirement for 30 consecutive business days, as per Nasdaq Listing Rule 5550(a)(2). This bid price deficiency could impact Silexion's continued listing on the Nasdaq Capital Market. While the letter does not immediately affect the trading of Silexion's ordinary shares or warrants, it will be considered by the Nasdaq hearings panel in deciding whether the company can remain listed. Silexion has until September 19, 2025, to meet compliance terms and achieve the required standards for listing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。